{"filing":{"accession_number":"0001213900-26-081982","cik":"0001075880","ticker":"KZIA","company_name":"KAZIA THERAPEUTICS LTD","form":"6-K","filing_date":"2026-07-28","report_date":"2026-07-28","primary_document":"ea029943501-6k_kazia.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1075880/000121390026081982/ea029943501-6k_kazia.htm"},"events":[{"id":20904,"run_id":18824,"accession_number":"0001213900-26-081982","anchor_item_number":"EX-99.1","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"Kazia announced the filing of a provisional patent application for a novel therapeutic strategy to prevent metastatic recurrence in triple-negative breast cancer, supported by preclinical data showing 95% reduction in residual disease and 40% reduction in lung metastatic burden. The company also announced plans to broaden clinical development of paxalisib into earlier-stage TNBC. This is a material operational/strategic milestone—a significant expansion of the drug candidate's development pathway and intellectual property protection—but does not fit the specific event categories of earnings release, executive changes, M\u0026A, impairment, or other named types. The preclinical findings and patent filing represent a meaningful advancement in the company's pipeline strategy that would affect a reasonable investor's assessment of paxalisib's potential market opportunity.","company_name":"KAZIA THERAPEUTICS LTD","ticker":"KZIA","filing_date":"2026-07-28","form":"6-K","submitted_at":null,"items":[{"id":20408,"accession_number":"0001213900-26-081982","item_number":"EX-99.1","item_title":"ea029943501ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Kazia announced the filing of a provisional patent application for a novel therapeutic strategy to prevent metastatic recurrence in triple-negative breast cancer, supported by preclinical data showing 95% reduction in residual disease and 40% reduction in lung metastatic burden. The company also announced plans to broaden clinical development of paxalisib into earlier-stage TNBC. This is a material operational/strategic milestone—a significant expansion of the drug candidate's development pathway and intellectual property protection—but does not fit the specific event categories of earnings release, executive changes, M\u0026A, impairment, or other named types. The preclinical findings and patent filing represent a meaningful advancement in the company's pipeline strategy that would affect a reasonable investor's assessment of paxalisib's potential market opportunity.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-07-28T11:31:43.977226+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":20408,"accession_number":"0001213900-26-081982","item_number":"EX-99.1","item_title":"ea029943501ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Kazia announced the filing of a provisional patent application for a novel therapeutic strategy to prevent metastatic recurrence in triple-negative breast cancer, supported by preclinical data showing 95% reduction in residual disease and 40% reduction in lung metastatic burden. The company also announced plans to broaden clinical development of paxalisib into earlier-stage TNBC. This is a material operational/strategic milestone—a significant expansion of the drug candidate's development pathway and intellectual property protection—but does not fit the specific event categories of earnings release, executive changes, M\u0026A, impairment, or other named types. The preclinical findings and patent filing represent a meaningful advancement in the company's pipeline strategy that would affect a reasonable investor's assessment of paxalisib's potential market opportunity.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-07-28T11:31:43.977226+00:00","company_name":"KAZIA THERAPEUTICS LTD","ticker":"KZIA","filing_date":"2026-07-28"}]}